Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trifluoromethionine is a non-proteinogenic amino acid and a fluorinated analogue of methionine in which the methyl group of methionine is replaced by a trifluoromethyl group. It is classified as an organofluorine compound and belongs to the class of L-alpha-amino acids. Trifluoromethionine acts as an antimicrobial agent with demonstrated in vitro toxicity against anaerobic protozoan parasites such as Trichomonas vaginalis and certain bacterial strains expressing methionine gamma lyase (MGL). Its mechanism involves targeting enzymes like methionyl-tRNA synthetase (methionyl-tRNA ligase), methionine aminopeptidase, and particularly relies on the presence of MGL for its cytotoxic effects. Resistance can develop through downregulation or absence of MGL activity[5][7][8]. The compound has been used primarily in research settings to study protein engineering, enzyme mechanisms, and antimicrobial activity rather than as an approved pharmaceutical drug[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trifluoromethionine.